Lannett Company (LCI)
Lannett Company Revenue Per Share TTM: 3.978
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
LCI Revenue Per Share TTM Rankings
| Overall | 22nd percentile | 3361 of 4331 |
| Sector | 48th percentile | 230 of 450 in Healthcare |
| Industry | 67th percentile | 12 of 37 in Drug Manufacturers - Other |
LCI Revenue Per Share TTM Range, Past 5 Years
| Minimum | 2.608 | Mar 2008 |
| Maximum | 5.105 | Sep 2009 |
| Average | 4.018 |
About Revenue Per Share (TTM)
Revenue Per Share (TTM) shows how much of the past four quarters' revenue is attributable to each share of common stock.
Learn More
You may also be interested in these LCI related companies
LCI News
$LCI forms bullish "Continuation Wedge" chart pattern. http://stks.co/3mUO
about 19 days ago by RecogniaEvents
about 19 days ago by RecogniaEvents
Lannett to Report Fiscal 2012 Third-Quarter Financial Results and Host Conference Call on Tuesday, May 8
May 02, 8:05AM Business Wire
May 02, 8:05AM Business Wire
$LCI forms bullish "Continuation Wedge" chart pattern. http://stks.co/3Ulq
about 35 days ago by RecogniaEvents
about 35 days ago by RecogniaEvents
Lannett to Present at Roth 24th Annual Orange County Growth Stock Conference
Mar 06, 8:55AM Business Wire
Mar 06, 8:55AM Business Wire
Obseity control drug approved by FDA, second approval in a week, $LCI 5.22+0.13
about 117 days ago by silverjet2
about 117 days ago by silverjet2
Lannett (LCI) receives FDA approval for ANDA supplement for phentermine HCI capsules, 15 mg
Jan 31, 8:12AM Street Insider
Jan 31, 8:12AM Street Insider
Lannett Receives FDA Approval for ANDA Supplement for Phentermine HCL Capsules, 15 mg
Jan 31, 8:05AM Benzinga
Jan 31, 8:05AM Benzinga
Lannett to Report Fiscal 2012 Second-Quarter Financial Results and Host Conference Call on Tuesday, February 7
Jan 30, 3:47PM Business Wire
Jan 30, 3:47PM Business Wire
$LCI today announced FDA approval of its Abbreviated New Drug Application (ANDA) for Hydrochlorothiazide Capsules, 12.5 mg.
about 121 days ago by silverjet2
about 121 days ago by silverjet2
FDA Grants Lannett (LCI) Approval for Hydrochlorothiazide Capsules, 12.5 mg
Jan 30, 8:16AM Street Insider
Jan 30, 8:16AM Street Insider
Low-debt growth $LCI held by insiders and $$$ managers, should have a +ve 2012 with recent FDA approvals and increased production, Long
about 124 days ago by silverjet2
about 124 days ago by silverjet2
Lannett Reaches Special Protocol Assessment Agreement with FDA for Cocaine HCl Phase III Trial
Jan 04, 11:40AM Benzinga
Jan 04, 11:40AM Benzinga
$LCI filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/1ZJY
about 167 days ago by MarketBrief
about 167 days ago by MarketBrief
Lannett receives FDA approval for triamterene with hydrochlorothiazide capsules
Dec 12, 2:46PM theflyonthewall.com
Dec 12, 2:46PM theflyonthewall.com
Lannett Receives FDA Approval for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules
Dec 12, 2:44PM Benzinga
Dec 12, 2:44PM Benzinga
Lannett to Present at Oppenheimer 22nd Annual Healthcare Conference on December 14th
Dec 07, 8:00AM Business Wire
Dec 07, 8:00AM Business Wire
Lannett to Present at Lazard Capital Markets 8th Annual Healthcare Conference on November 15th
Nov 10, 11:20AM Business Wire
Nov 10, 11:20AM Business Wire
Lannett to Report Fiscal 2012 First-Quarter Financial Results and Host Conference Call on Thursday, November 3, 2011
Oct 27, 12:24PM Business Wire
Oct 27, 12:24PM Business Wire
Lannett (LCI) Receives FDA Approval for Diethylpropion HCl XR Tabs ANDA
Oct 24, 1:40PM Street Insider
Oct 24, 1:40PM Street Insider
Lannett receives FDA approval for Diethylpropion HCI extended release tablets
Oct 24, 1:36PM FlyOnTheWall
Oct 24, 1:36PM FlyOnTheWall
Lannett Receives FDA Approval for Diethylpropion HCl Extended Release Tablets, 75 mg
Oct 24, 1:36PM Benzinga
Oct 24, 1:36PM Benzinga
Lannett $LCI gets FDA approval for loxapine capsules in 5, 10, 25 and 50 MG
about 246 days ago by Street_Insider
about 246 days ago by Street_Insider
$LCI--CEO purchased 20,467 shares at $3.90. Stock trading at $3.95. Do your own research, low floater.
about 261 days ago by MicroInsider
about 261 days ago by MicroInsider
$LCI initated position at 4.70, looking for .50-1.00 in 2 weeks on drug approval, possible buyout
about 317 days ago by CollegeStockTrader
about 317 days ago by CollegeStockTrader
$LCI takes a 5% hit after #FDA approval. Has several more to go? Strange reaction. Crazy Monday!
about 338 days ago by msgtretusaf
about 338 days ago by msgtretusaf
$LCI....fundies ae ok.....need more liquidity, higher price action before I play this one.
about 341 days ago by BreakoutTheory
about 341 days ago by BreakoutTheory
$LCI The FDA must be backed up hope it's out tomorrow morning traded low volume after hours
about 341 days ago by TylerTrimbath
about 341 days ago by TylerTrimbath
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LCI | 4.09 | +0.01 | +0.25% | 115.71M |
| LCC | 12.67 | +0.05 | +0.40% | 2.046B |
| JPM | 33.20 | -0.43 | -1.28% | 128.38B |
| JPG | 12.77 | -0.07 | -0.55% | |
| JOY | 58.97 | -3.35 | -5.38% | 6.675B |
| JOUT | 18.15 | -0.13 | -0.71% | 180.42M |
| JOSB | 44.74 | -3.05 | -6.38% | 1.330B |
| JOEZ | 1.04 | -0.03 | -2.80% | 69.43M |
| JOE | 16.57 | -0.37 | -2.18% | 1.563B |
| JOBS | 46.11 | -1.09 | -2.31% | 1.337B |
